Table 4.

Detection rates for significant and insignificant prostate cancer of MRI/ultrasound fusion targeted biopsy versus transperineal template saturation mapping biopsy (n = 80).

	MRI/US-TBx	TTMB	p value (MRI versus TTMB)	CBS	p value (MRI versus CBS)
Any prostate cancer, n (%)	40 (50%)	48 (60%)	0.13	55 (69%)	<0.01
Significant prostate cancer, n (%)	32 (40%)	28 (35%)	0.48	39 (49%)	0.02
Insignificant prostate cancer, n (%)	8 (10%)	20 (25%)	0.01	16 (20%)	0.04

MRI/US-TBx = MRI/transrectal ultrasound fusion targeted biopsy, TTMB = transperineal template guided mapping biopsy, CBS = combined biopsy strategy (MRI/US-TBx + TTMB), and n = number.